| A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder F Bolognani, M del Valle Rubido, L Squassante, C Wandel, M Derks, ... Science translational medicine 11 (491), eaat7838, 2019 | 104 | 2019 |
| Adaptive behavior in autism: minimal clinically important differences on the Vineland‐II CH Chatham, KI Taylor, T Charman, X Liogier D'Ardhuy, E Eule, A Fedele, ... Autism Research 11 (2), 270-283, 2018 | 103 | 2018 |
| Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial J Sahni, PU Dugel, SS Patel, ME Chittum, B Berger, M del Valle Rubido, ... JAMA ophthalmology 138 (9), 955-963, 2020 | 87 | 2020 |
| A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder D Umbricht, M del Valle Rubido, E Hollander, JT McCracken, F Shic, ... Neuropsychopharmacology 42 (9), 1914-1923, 2017 | 78 | 2017 |
| In search of biomarkers for autism spectrum disorder M Del Valle Rubido, JT McCracken, E Hollander, F Shic, J Noeldeke, ... Autism research 11 (11), 1567-1579, 2018 | 32 | 2018 |
| Exploring social biomarkers in high-functioning adults with autism and Asperger’s versus healthy controls: A cross-sectional analysis M Del Valle Rubido, E Hollander, JT McCracken, F Shic, J Noeldeke, ... Journal of Autism and Developmental Disorders 50, 4412-4430, 2020 | 11 | 2020 |
| The effects of a novel vasopressin V1a antagonist on orienting to biological motion F Shic, M del Valle Rubido, E Hollander, SS Jeste, JT McCracken, ... AGE 23, 5.1, 2014 | 3 | 2014 |
| 5.13 Effects of Balovaptan on Health-Related Quality of Life of Adult Men With ASD: Results From a Phase 2 Randomized Double-Blind Placebo Controlled Study (Vanilla) L Squassante, F Bolognani, J Smith, L Murtagh, P Fontoura, O Khwaja, ... Journal of the American Academy of Child & Adolescent Psychiatry 57 (10), S231, 2018 | 2 | 2018 |
| A multi-center, observational study to explore the relationship between exploratory biomarkers and functional dimensions in adults with autistic spectrum disorders MDV Rubido, E Hollander, J McCracken, F Shic, J Noeldeke, L Boak, ... European Neuropsychopharmacology 2 (26), S193, 2016 | 2 | 2016 |
| Correction to: Exploring Social Biomarkers in High‑Functioning Adults with Autism and Asperger’s Versus Healthy Controls: A Cross‑Sectional Analysis MDV Rubido, E Hollander, JT McCracken, F Shic, J Noeldeke, L Boak, ... Journal of Autism and Developmental Disorders 50 (12), 4431, 2020 | | 2020 |
| Effects of Balovaptan on Health-Related Quality of Life of Adult Men With ASD: Results From a Phase 2 Randomized Double-Blind Placebo Controlled Study (VANILLA) T Willgoss, L Squassante, F Bolognani, J Smith, L Murtagh, P Fontoura, ... 65th Annual Meeting, 2018 | | 2018 |
| P. 7. d. 011 Results from a phase I proof-of-mechanism study with a vasopressin 1A receptor antagonist in autism spectrum disorder MDV Rubido, D Umbricht, F Shic, JT McCracken, L Scahill, O Khwaja, ... European Neuropsychopharmacology, S646-S647, 2015 | | 2015 |
| Olfaction is Associated with Ability to Recognize Emotions in High Functioning Autistic Subjects D Umbricht, MV Rubido, F Shic, JT McCracken, L Scahill, O Khwaja, ... NEUROPSYCHOPHARMACOLOGY 39, S584-S584, 2014 | | 2014 |
| Clinical and Biomarker Effects of a Novel Vasopressin 1a Receptor Antagonist (RG7713) vs. Placebo in High Functioning Adult Autism E Hollander, M del Valle Rubido, O Khwaja, L Squassante, CJ Ferretti, ... NEUROPSYCHOPHARMACOLOGY 39, S374-S375, 2014 | | 2014 |
| Affective Speech Recognition Clinical Biomarker Effects of a Novel Vasopressin 1a Receptor Antagonist Vs Placebo in Adult Autism E Hollander, MV Rubido, O Khwaja, L Squassante, CJ Ferretti, BP Taylor, ... BIOLOGICAL PSYCHIATRY 75 (9), 324S-325S, 2014 | | 2014 |
| Deficient Olfaction is Associated with Impaired Ability to Recognize Emotions in High Functioning Autistic Subjects and may be Improved by a Vasopressin 1a Receptor Antagonist D Umbricht, MV Rubido, F Shik, JT McCracken, L Scahill, O Khwaja, ... BIOLOGICAL PSYCHIATRY 75 (9), 388S-388S, 2014 | | 2014 |
| Number of text pages: 28 CH Chatham, KI Taylor, T Charman, XL D’ardhuy, E Eule, A Fedele, ... | | |
| King’s Research Portal L Murtagh, M del Valle Rubido, A San Jose Caceres, J Sevigny, L Sikich, ... | | |
| Impact of Sleep Disorders on Anxiety-Related Clinical Scales in Individuals With Autism Y Zhu, Y Liu, T Wiese, M del Valle Rubido | | |
| Prevalence of Sleep Disorders and Patterns of Medication Use in Individuals With Neurodevelopmental Disorders Using Health Insurance Claims Data From the United States M Johnson, A Yakubu, T Wiese, M del Valle Rubido Autism 2, 94.9, 0 | | |
